Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, is pleased to announce that it has entered into a license agreement with Astrea Bioseparations ("Astrea") for the use of the Affimer platform in affinity purification applications.
More